Last reviewed · How we verify
intravesical onabotulinumtoxinA injection
At a glance
| Generic name | intravesical onabotulinumtoxinA injection |
|---|---|
| Also known as | BOTOX |
| Sponsor | Buddhist Tzu Chi General Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections (PHASE4)
- Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial (NA)
- The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder (PHASE4)
- Prophylactic Analgesia for Bladder Botox Injections (PHASE4)
- Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections (PHASE4)
- Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections (PHASE4)
- Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)
- Different Injection Site Maps & Intravesical Botulinum Toxin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: